ANGO 最新10-Q变化
将 ANGO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-10-08 与上一份 10-Q · 2026-04-02
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +35 | −52 | ~28 | 18 |
| 市场风险(第3项) | 文字有新增/删除 | 0 | 0 | ~3 | 4 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | 0 | −2 | ~1 | 6 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-10-08
Our Med Tech revenue, comprised of Auryon, NanoKnife and the thrombus management platform, grew 13.2% in the first quarter of fiscal year 2027 driven by increased sales in Auryon, NanoKnife and the thrombus management products. Our Med Device revenue grew by 1.4% in the first quarter of fiscal year …
For the three months ended August 31, 2026, the Company reported net loss of $7.1 million, or diluted loss per share of $0.17, on net sales of $80.9 million, compared with a net loss of $10.9 million, or diluted loss per share of $0.26, on net sales of $75.7 million during the same quarter of the pr…
For the three months ended August 31, 2026, net sales increased $5.2 million to $80.9 million compared to the same period in the prior year. At August 31, 2026, the Company had a backlog of $2.7 million.
•Increased sales of the thrombus management platform of $0.4 million, which was driven by an increase in AlphaVac sales of $1.2 million and was partially offset by a decrease in AngioVac and thrombolytic sales of $0.5 and $0.4 million, respectively; and
•Increased NanoKnife sales of $1.9 million, which was driven by increased disposable and capital sales.
相对上期删除的文字 · 来源:10-Q · 2026-04-02
•Net loss increased by $3.7 million to a loss of $8.1 million
•Med Tech and Med Device growth of 19.1% and 3.2%, respectively
•Med Tech gross margin increased 10 bps to 63.3% and Med Device gross margin decreased 20 bps to 47.6%
•Net loss decreased by $2.6 million to a loss of $25.3 million
Our Med Tech revenue, comprised of Auryon, the thrombus management platform and NanoKnife, grew 19.0% in the third quarter of fiscal year 2026 driven by growth across all product lines. Our Med Device revenue grew by 1.2% in the third quarter of fiscal year 2026 driven by growth in the Core and Veno…
其他信息
相对上期删除的文字 · 来源:10-Q · 2026-04-02
Transition and Retirement Agreement, dated as of February 3, 2026, by and between AngioDynamics, Inc. and James C. Clemmer
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议